Eli Lilly took part in the biopharmaceutical startup’s $155m series B while Weiqiao Pioneering led a $112m series A-plus round for robotic truck developer DeepWay.
Funding
US-based biopharmaceutical therapeutics developer ArriVent Biopharma raised $155m in series B funding from investors including pharmaceutical firm Eli Lilly’s regional fund, Lilly Asia Ventures. The round was co-led by Sofinnova Investments and General Catalyst and included Catalio Capital Management, HBM Healthcare Investments, Shanghai Healthcare Capital, Sequoia China, AIHC Capital, Terra Magnum Capital Partners, Unicorn Capital Partners Limited, Infinitum Asset Management, OrbiMed, Octagon…
